Some might argue that Gilead Science s (NASDAQ: GILD) is back. The stock trounced the S&P 500 in 2022. Despite a slower start this year, Gilead appears to be in pretty good shape to resume its momentum.
The big drugmaker reported its 2022 full-year and fourth-quarter results after the market closed on Thursday. CEO Dan O'Day stated in the press release announcing the numbers, "2022 marked Gilead's strongest full-year growth in our base business since HCV sales peaked in 2015."
Is Gilead Sciences stock a buy after its strongest results in seven years?
For further details see:
Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?